TOX3 and colorectal carcinoma: The most prevalent events were recurrent in three tumors each (1.5%) and affected a region on 17q12-q21.1, confirming the existence of a CRC subgroup with extreme ERBB2 amplification (22, 27 and 97 additional copies), and a region on 16q12.1–12.2 (23, 44 and 47 additional copies), identifying CASC16 and the transcription factor TOX3 as novel recurrently amplified genes (Table 1, Fig. 1c, Supplementary Fig. 2e).